Oncology and Cellular Immunology, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Department of Biomedicine, University of Bergen, Bergen, Norway; Laboratory for Immune Cell Systems, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Semin Immunol. 2019 Feb;41:101273. doi: 10.1016/j.smim.2019.04.001. Epub 2019 Apr 9.
The advance of immunotherapies has revolutionized the treatment of cancer patients. Mostly agents modulating the adaptive immune system are currently used. More recently, attempts to stimulate the innate immune system are being promoted for clinical evaluation. Innate lymphoid cells (ILCs) are a highly plastic population of immune cells crucial for tissue homeostasis and the regulation of immune responses and maybe a promising target to improve current cancer immunotherapies. Although we have made significant progress in understanding ILC biology, their impact on tumor development, progression and therapy is controversial. In this review, we discuss the recent advances of ILC function and plasticity in the context of cancer.
免疫疗法的进步彻底改变了癌症患者的治疗方式。目前主要使用的是调节适应性免疫系统的药物。最近，人们尝试刺激先天免疫系统以进行临床评估。先天淋巴细胞 (ILC) 是一类具有高度可塑性的免疫细胞，对组织稳态和免疫反应的调节至关重要，也许是改善当前癌症免疫疗法的有前途的靶点。尽管我们在理解 ILC 生物学方面取得了重大进展，但它们对肿瘤发展、进展和治疗的影响仍存在争议。在这篇综述中，我们讨论了 ILC 功能和可塑性在癌症背景下的最新进展。
